BioCryst Pharmaceuticals share price today

BioCryst Pharmaceuticals, Inc.'s share price was $8.24 at the close on 4 November 2026. It has been moving sideways for 7 weeks. That is 6.0% below its average price over the last 200 trading days. In the last 52 weeks it traded between $6 and $10, and at that close it sat 46% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today BioCryst Pharmaceuticals, Inc. is in stage 1. The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 9 weeks running.

Over the last 10 years the share price moved +167% while the S&P 500 moved +261%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 4 September 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

BioCryst Pharmaceuticals, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

BioCryst Pharmaceuticals is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

BioCryst Pharmaceuticals, Inc. earned $78.4 M of net profit in the Jun 2026 quarter, +1,441.7% on the same quarter a year earlier. Full-year FY25 profit was $264 M. That is 35.9% of the quarter's revenue. The same quarter a year earlier earned $5.1 M. 7 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

BioCryst Pharmaceuticals, Inc. reported $218 M of revenue in the Jun 2026 quarter, +33.6% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 53.6% a year on average. The last full year, FY25, came in at $875 M.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $941 M.

FY25 revenue was $875 M, +94.1% on the year before.

Recent pace: the last four quarters grew +71.6% on average, against 53.6% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +68.7%, against +56.9% a year over the last 8 quarters (accelerating).

BioCryst Pharmaceuticals, Inc.'s operating margin was 45.1% in the Jun 2026 quarter, 26.9 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −113.1% and 39.7%. The latest quarter is above every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Across 5 years it has been between −113.1% and 39.7%, and FY25's 39.7% is the highest of them.

Why the margin moved: operating margin changed +26.9 percentage points on the year while gross margin changed +2.7 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

BioCryst Pharmaceuticals, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $347 M of operating cash against $264 M of profit. After $2.5 M of spending on assets, $345 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

BioCryst Pharmaceuticals, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $5.8 M on assets over the last 3 years. Averaged over those years that is 0.2% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $5.8 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

BioCryst Pharmaceuticals, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values BioCryst Pharmaceuticals, Inc. at 2.4× its FY25 revenue of $875 M. The P/E comes back here once profit turns positive.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

BioCryst Pharmaceuticals, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading.

The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

BioCryst Pharmaceuticals, Inc. earned a ROE of −221% in FY25. Its return on capital used (ROIC) is 98.7 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 30.2% net margin and 1.70× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 30.2% net margin × 1.70× asset turnover × −4.32× leverage (assets divided by equity) ≈ −221.8% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 105.8% − 7.1% = +98.7 percentage points. The 7.1% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value.

BioCryst Pharmaceuticals, Inc.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from −5.55 in FY21 to −4.01 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

12.0% of BioCryst Pharmaceuticals, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 5.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For BioCryst Pharmaceuticals, Inc., the Z-score is 0.52. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 0.52 is inside the danger zone, so the balance sheet is a real risk.

58.3 out of 100, rank 8 of 28 in Drug Manufacturers - Specialty & Generic, with 64% of the evidence available.

BioCryst Pharmaceuticals, Inc. scores 58.3 out of 100 against the 28 companies it is compared with in Drug Manufacturers - Specialty & Generic, ranking 8. Earnings are strong; relative strength in its sector is -18% and the one-year return is 16.2%.

The four parts add up to the total exactly: 25.6 + 18.1 + 11 + 3.6 = 58.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

BioCryst Pharmaceuticals ranks 8 of 28 Drug Manufacturers - Specialty & Generic companies on the 4-Factor Sector Score, with 58.3 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Drug Manufacturers - Specialty & Generic, all 28 compared on one page.

BioCryst Pharmaceuticals is the 24th largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: HUTCHMED (China), Trulieve Cannabis Corp. and Perrigo Company plc. Just below it: Xeris Biopharma Holdings, Inc., Alvotech and Phibro Animal Health Corporation.

Drug Manufacturers - Specialty & Generic companies close in size

21. HUTCHMED (China) Limited $2.4 billion
22. Trulieve Cannabis Corp. $2.2 billion
23. Perrigo Company plc $2.2 billion
24. BioCryst Pharmaceuticals, Inc. $2.1 billion
25. Xeris Biopharma Holdings, Inc. $1.9 billion
26. Alvotech $1.7 billion
27. Phibro Animal Health Corporation $1.6 billion